bluuebunny/crossref_metadata_2025_split huggingface dataset:
CEO compensation: does it pay to be green?
Authors: Stanwick Peter A. , Stanwick Sarah D. 
Published: August 2002

AbstractThe relationship between chief executive officer (CEO) compensation and various organizational variables (i.e., size, length of tenure of the CEO, board composition and firm performance) has been explored in academic research. However, the relationship between CEO compensation and the firm's reputation based on the firm's commitment to the community and the environment has been relatively unexamined in the academic research. This study's purpose is to empirically examine this relationship using the Fortune Reputation Index as revised by Brown and Perry (1995).Using a sample of 186 firms in 1990 and 188 firms in 1991, the relationships between CEO compensation and organization size, financial performance and environmental reputation are examined. The results of the study demonstrate that there is a strong relationship between CEO compensation and firm environmental reputation, firm size and firm financial performance. Copyright © 2001 John Wiley & Sons, Ltd. and ERP Environment
Randomized comparison of vasoseal and angioseal closure devices in patients undergoing coronary angiography and angioplasty
Authors: Shammas Nicolas W. , Rajendran Vijay R. , Alldredge Stephen G. , Witcik William J. , Robken Jon A. , Lewis J. Randolph , McKinney Dawn , Hansen Christena A. , Kabel M. Elizabeth , Harris Melodee , Jerin Michael J. , Bontu Prakash R. , Dippel Eric J. , Labroo Ajay 
Published: August 2002

AbstractAngioSeal (AS) and VasoSeal (VS) are collagen‐based arterial closure devices utilized to achieve earlier hemostasis and ambulation in diagnostic and interventional percutaneous procedures. To our knowledge, there has been no randomized studies comparing these two devices as approved for use in the United States. One hundred fifty‐seven patients were randomized to receive either the 8 Fr AS (n = 79) or VS (n = 78) closure device. Data on 95 patients who had coronary angiography (49 AS, 46 VS) and 55 patients who underwent angioplasty (28 AS, 27 VS) were completed. Heparin was not administered during the coronary angiogram procedure. The activated clotting time was kept at approximately 300 sec during angioplasty. Patients on coumadin or GP IIb/IIIa platelet inhibitors were not included in this study. The time unit interval to achieve hemostasis in this study was based on the time the AS tension spring was left over the common femoral artery following collagen deployment as per the manufacturer's instructions (20 min). Time to hemostasis, time to ambulation, and major and minor complications were prospectively recorded. Two‐tailed t‐test and chi‐square analysis were performed on continuous and dichotomous variables, respectively. For the angiogram‐only subgroup, time (min) to hemostasis (20.51 ± 4.36 vs. 18.59 ± 11.77; P = 0.30) and ambulation (145.71 ± 124 vs. 109.89 ± 60.37; P = 0.075) were not statistically different for the AS and VS, respectively. Similarly, for the angioplasty subgroup, time (min) to hemostasis (24.23 ± 12.70 vs. 19.57 ± 2.27; P = 0.077) and ambulation (607.32 ± 344.22 vs. 486.48 ± 200.37; P = 0.12) were not statistically different for both AS and VS, respectively. Furthermore, there were no statistical differences in deployment failure, major, minor, or total complication rates between the two devices. In the absence of GP IIb/IIIa inhibitors, VS and the 8 Fr AS devices have statistically similar time to hemostasis and ambulation as well as device failures and complication rates following coronary angiography and angioplasty. Cathet Cardiovasc Intervent 2002;55:421–425. © 2002 Wiley‐Liss, Inc.
Transient occlusion of an angioguard protection system by massive embolization during angioplasty of a degenerated aortocoronary saphenous vein graft
Authors: Kindel Martin , Spiller Paul 
Published: August 2002

AbstractDistal embolization is the most important complication of balloon dilatation of degenerated saphenous vein grafts. We describe a case of massive embolization associated with transient occlusion in which larger distal embolization and myocardial infarction were avoided despite transient but complete occlusion of a filter protection system (Angioguard). Cathet Cardiovasc Intervent 2002;55:501–504. © 2002 Wiley‐Liss, Inc.
Acute renal artery thrombosis treated by percutaneous rheolytic thrombectomy
Authors: Greenberg Jeffrey M. , Steiner Mark A. , Marshall J. Jeffrey 
Published: August 2002

AbstractRenal artery thrombosis or embolus is a rare condition that may lead to hypertension and renal failure. Treatment options in the past have had limited success. We present a case which demonstrates the use of percutaneous rheolytic therapy with the Angiojet atherectomy catheter to treat this condition in the acute setting. Cathet Cardiovasc Intervent 2002;56:66–68. © 2002 Wiley‐Liss, Inc.
Local delivery of paclitaxel using the double‐balloon perfusion catheter before stenting in the porcine coronary artery
Authors: Oberhoff Martin , Herdeg Christian , Al Ghobainy Rasool , Cetin Süha , Küttner Axel , Horch Barbara , Baumbach Andreas , Karsch Karl R. 
Published: August 2002

AbstractPaclitaxel is a new cancer chemotherapeutic agent that has been approved for clinical use in patients with a variety of different cancers. Paclitaxel inhibits cell proliferation by an action on microtubules. The aim of this study was to evaluate the safety and efficacy of locally delivered paclitaxel after coronary stent implantation. A novel double‐balloon perfusion catheter was used to deliver the drug locally in the pig coronary artery. Twenty‐seven domestic pigs underwent stent implantation of the left anterior descending artery. In the treatment group (n = 11), paclitaxel (10 ml;10 μmol/l) was delivered using the double‐balloon perfusion catheter prior to stent implantation. The control group received stent implantation only (n = 16). The animals were sacrificed 4 weeks later. Vessels were perfusion‐fixed and morphometric analysis was performed using conventional techniques. In addition, the extent of injury was determined at each stent‐strut area. Correlation of local injury and neointimal thickness was evaluated by linear regression. Neointimal thickness (paclitaxel 1.0 ± 0.4 vs. control 0.7 ± 0.3 mm), neointimal area (paclitaxel 4.1 ± 2.2 vs. control 2.4 ± 1.1 mm2), and the lumen area (paclitaxel 2.1 ± 1.9 vs. control 2.5 ± 0.9 mm2) did not show significant differences between both groups. Medial area (3.3 ± 2.3 vs. 1.6 ± 0.4 mm2) was larger in the vessels treated with paclitaxel (P < 0.05). Linear regression failed to show any difference in the response to injury between the two groups. Local delivery of paclitaxel with the double‐balloon‐perfusion catheter did not reduce neointima formation following stent implantation in native pig coronary arteries. Cathet Cardiovasc Intervent 2001;53:562–568. © 2001 Wiley‐Liss, Inc.
Angiographic prevalence and clinical predictors of left subclavian stenosis in patients undergoing diagnostic cardiac catheterization
Authors: English JoAnna L. , Carell Edgar S. , Guidera Steven A. , Tripp Henry F. 
Published: August 2002

AbstractThe angiographic prevalence, clinical predictors, and sensitivity and specificity of a bilateral arm blood pressure differential for predicting proximal left subclavian artery stenosis were established in 492 patients undergoing cardiac catheterization. Seventeen subjects (3.5%) in the overall population and nine subjects (5.3%) with potential surgical coronary disease had proximal left subclavian stenosis. Precatheterization evidence of peripheral vascular disease (PVD) was the only predictor of subclavian stenosis in the overall population (P < 0.001; OR = 7.9; 95% CI = 2.6–24.3) and in patients with potential surgical coronary disease (P = 0.04; OR = 5.4; 95% CI = 1.1–27.2). Both a bilateral blood pressure differential of > 10 mm Hg and of ≥20 mm Hg had a good specificity but a poor sensitivity for predicting left subclavian stenosis. Thus, left subclavian angiography should be performed in patients with surgical coronary disease with either an arm blood pressure differential of > 10 mm Hg or with other precatheterization evidence of PVD. Cathet Cardiovasc Intervent 2001;54:8–11. © 2001 Wiley‐Liss, Inc.
iSPOT: a web tool for the analysis and recognition of protein domain specificity
Authors: Brannetti Barbara , Zanzoni Andreas , Montecchi‐Palazzi Luisa , Cesareni Gianni , Helmer‐Citterich Manuela 
Published: August 2002

AbstractMethods that aim at predicting interaction partners are very likely to play an important role in the interpretation of genomic information. iSPOT (iSpecificity Prediction Of Target) is a web tool (accessible at http://cbm.bio.uniroma2.it/iSPOT) developed for the prediction of protein‐protein interaction mediated by families of peptide recognition modules. iSPOT accesses a database of position specific residue‐residue interaction frequencies for members of the SH3 and PDZ protein domain families. The software utilises this database to provide a score for any potential domain peptide interaction. iSPOT: 1. evaluates the likelihood of the interaction between any of the peptides contained in an input protein and a list of domains of the two different families; 2. searches in the SWISS‐PROT database for potential partners of a query domain; and 3. has access to a repository of all the domain/target peptide interaction data. Copyright © 2001 John Wiley & Sons, Ltd.
The interaction between endopolygalacturonase from Fusarium moniliforme and PGIP from Phaseolus vulgaris studied by surface plasmon resonance and mass spectrometry.
Authors: Mattei Benedetta , Cervone Felice , Roepstorff Peter 
Published: August 2002

AbstractA combination of surface plasmon resonance (SPR) and matrix‐assisted laser‐desorption‐ionization‐time‐of‐flight
mass spectrometry (MALDI‐TOF‐MS) was used to study the interaction between endopolygalacturonase
(PG) from Fusarium moniliforme and a polygalacturonase‐inhibiting
protein (PGIP) from Phaseolus vulgaris. PG hydrolyses the homogalacturonan
of the plant cell wall and is considered an important pathogenicity factor
of many fungi. PGIP is a specific inhibitor of fungal PGs and is thought to
be involved in plant defence against phytopathogenic fungi. SPR was used either
to study the effect of the PG glycosylation on the formation of the complex
with PGIP, and as a sensitive affinity capture of an interacting peptide from
a mixture of PG fragments obtained by limited proteolysis. Mass spectrometry
allowed to characterise the interacting peptide eluted from the sensor surface.
Copyright © 2001 John Wiley & Sons, Ltd.
REGIA, an EU project on functional genomics of transcription factors from Arabidopsis thaliana
Authors: Paz‐Ares Javier ,   The REGIA Consortium
Published: August 2002

AbstractTranscription factors (TFs) are regulatory proteins that have played a
pivotal role in the evolution of eukaryotes and that also have great biotechnological
potential. REGIA (REgulatory Gene Initiative
in Arabidopsis) is an EU‐funded project involving 29 European laboratories
with the objective of determining the function of virtually all transcription
factors from the model plant, Arabidopsis thaliana. REGIA involves:
1. the definition of TF gene expression patterns in Arabidopsis;
2. the identification of mutations at TF loci; 3. the ectopic expression
of TFs (or derivatives) in Arabidopsis and in crop plants; 4. phenotypic
analysis of the mutants and mis‐expression lines, including both RNA and metabolic
profiling; 5. the systematic analysis of interactions between TFs; and 6.
the generation of a bioinformatics infrastructure to access and integrate
all this information. We expect that this programme will establish the full
biotechnological potential of plant TFs, and provide insights into hierarchies,
redundancies, and interdependencies, and their evolution. The project involves
the preparation of both a TF gene array for expression analysis and
a normalised full length open reading frame (ORF) library of TFs in a yeast
two hybrid vector; the applications of these resources should extend beyond
the scope of this programme. Copyright © 2002 John Wiley & Sons,
Ltd.
MaizeDB – a functional genomics perspective
Authors: Polacco Mary , Coe Ed , Fang Zhiwei , Hancock Denis , Sanchez‐Villeda Hector , Schroeder Steve 
Published: August 2002

AbstractMaizeDB (http://www.agron.missouri.edu/)
has existed since the early 90's as a genome‐specific database that is
grounded in genetic maps, their documentation and annotation. The database
management system is robust and has continuously been Sybase. In this brief
review we provide an introduction to the database as a functional genomics
tool and new accesses to the data: 1) probe tables by bin location 2) BLAST
access to map data 3) cMap, a comparative map graphical tool. Copyright © 2002 John Wiley & Sons, Ltd.
Definition of the gene content of the human genome: the need for deep experimental verification
Authors: Simpson Andrew J. G. , de Souza Sandro J. , Camargo Anamaria A. , Brentani Ricardo R. 
Published: August 2002

AbstractBased on the analysis of the drafts of the human genome sequence, it is being speculated that our species may possess an unexpectedly low number of genes. The quality of the drafts, the impossibility of accurate gene prediction and the lack of sufficient transcript sequence data, however, render such speculations very premature. The complexity of human gene structure requires additional and extensive experimental verification of transcripts that may result in major revisions of these early estimates of the number ofhuman genes. Copyright © 2001 John Wiley & Sons, Ltd.
Preparation of (R)‐ and (S)‐α‐methyldopa from a chiral hydantoin containing the α‐phenylethyl group
Authors: LeóN‐Romo José Luis , Virues Claudia I. , Aviña Judit , Regla Ignacio , Juaristi Eusebio 
Published: August 2002

AbstractChiral hydantoin (S)‐1 was prepared in good yield from phenyl isocyanate and N‐[(S)‐α‐phenylethyl]glycinate, (S)‐3. Enolate (S)‐1‐Li was methylated in high yield and good diastereoselectivity. In contrast, a second alkylation reaction of methylated enolate (S)‐4‐Li proceeded with essentially no diastereoselectivity. Nevertheless, dialkylated hydantoins, (S,S)‐7 and (S,R)‐7, could be readily separated by flash chromatography and subsequent hydrolysis of either derivative afforded the desired (S)‐L‐α‐methyldopa or (R)‐D‐α‐methyldopa in good yield. Chirality 14:144–150, 2002. © 2002 Wiley‐Liss, Inc.
Atropisomerism as a probe of restrictions to motion above and below the glass transition temperature of Polymers
Authors: Park JI‐Woong , Green Mark M. 
Published: August 2002

AbstractThis short review and interpretation of work conducted in the authors' laboratory concerns the use of atropisomeric 1,1′‐binaphthyl derivatives to gain information about the glassy properties of polymers. Bridged binaphthyls appended with oligophenyl paddles are found to yield a series of probes whose racemization kinetics reveal new kinds of information concerning the basis of the time scale and length scale for the restrictions to motion and the heterogeneity of the polymeric glassy state. Because the time scale of the racemization is slower than all other glass probes used previously, new kinds of information were gained for the first time below the glass transition temperature. Chirality 14:209–214, 2002.© 2002 Wiley‐Liss, Inc.
Competitive intelligence and the product life cycle
Authors: Burkhardt Kimberly E. 
Published: August 2002

AbstractThe types of intelligence efforts used by CI professionals depend, in part, on an understanding—and appreciation—of the product life cycle. During the initial stage of market introduction, the role of CI will be to identify and monitor potential competitors. Once potential competition is identified, strategic planning will be needed to assess—and then implement—methodologies appropriate for the evolving competitive environment. During the advanced stages of growth and maturity, competitive threats will change in quantity and/or quality; these will be active transitional periods for intelligence professionals. During the seemingly inevitable decline stage of products and markets, the CI professional will need to help prolong profitability and to prevent as much market loss as possible through a variety of strategies. As a product life cycle draws to a close, CI practitioners can pull together acquired knowledge of market competition, which can then be applied to future markets. In sum, the role of the CI professional is to gather, assess, and disseminate intelligence that will aid the firm in maintaining a competitive advantage through all stages of the product life cycle. © 2001 John Wiley & Sons, Inc.
Host focal adhesion protein domains that bind to the translocated intimin receptor (Tir) of enteropathogenic Escherichia coli (EPEC)
Authors: Huang Lily , Mittal Balraj , Sanger Joseph W. , Sanger Jean M. 
Published: August 2002

AbstractEnteropathogenic Escherichia coli (EPEC) attach to the plasma membrane of infected host cells and induce diarrhea in a variety of farm animals as well in humans. These bacteria inject a three‐domain protein receptor, Tir (translocated intimin receptor), that is subsequently inserted into the plasma membrane. EPEC induce the host cell to form membrane‐covered actin‐rich columns called pedestals. Focal adhesion constituents, alpha‐actinin, talin, and vinculin, are localized along the length of the pedestals and we have previously reported they bind the two cytoplasmic domains of Tir, (Tir I and Tir III) [Freeman et al., 2000: Cell Motil. Cytoskeleton 47:307–318]. In the present study, various constructs were made expressing different regions of these three focal adhesion proteins to determine which domains of the proteins bound Tir I. Three different assays were used to detect Tir I/host protein domain interactions. In co‐precipitation assays, His‐Tir I bound to the 27‐kDa region of alpha‐actinin; to four different domains of talin; and to the N‐terminal domain of the vinculin head and the vinculin tail domain. A yeast two‐hybrid analysis of Tir I and the various focal adhesion fusion proteins revealed a region near the C‐terminus of talin was the only domain to interact with Tir I. Finally, to assess direct binding interactions, biotinylated Tir I was used in overlay assays and confirmed the binding of Tir I with the 27‐kDa region of alpha‐actinin, the four regions of talin, and the vinculin tail. These binding interactions between hostfocal adhesion proteins and EPEC Tir may facilitate the adhesion of EPEC to the host cell surface. Cell Motil. Cytoskeleton 52:255–265, 2002. © 2002 Wiley‐Liss, Inc.
Irinotecan hydrochloride for the treatment of recurrent and refractory non‐Hodgkin lymphoma
Authors: Sugiyama Katsuki , Omachi Ken , Fujiwara Keiichi , Saotome Takashi , Mizunuma Nobuyuki , Takahashi Shunji , Ito Yoshinori , Aiba Keisuke , Horikoshi Noboru 
Published: August 2002

AbstractBACKGROUNDIrinotecan hydrochloride (CPT‐11) has a broad range of antitumor activity and has demonstrated little cross‐resistance with doxorubicin or vincristine. In the current study, the authors investigated the efficacy and adverse effects of irinotecan in the treatment of recurrent and refractory non‐Hodgkin lymphoma, for which current therapies appear to be unsatisfactory.METHODSIrinotecan was administered by intravenous infusion at a dose of 40 mg/m2/day for 3 days, and this regimen was repeated 2–3 times at weekly intervals, followed by 2 weeks off therapy. The subjects were 48 patients with recurrent or refractory non‐Hodgkin lymphoma. The histologic classification (Working Formulation) was low grade in 8 patients, intermediate grade in 36 patients, high grade in 1 patient, and other (angiocentric lymphoma, Ki‐1 lymphoma, and unidentified) in 3 patients.RESULTSForty‐five patients were determined to be evaluable. Therapy resulted in a complete disease remission in 2 patients and a partial remission in 15 patients. The response rate was 37.8%. The median duration of response was 64 days and the median time to disease progression was 77 days. The median survival time was 422 days. Major adverse reactions included myelosuppression and gastrointestinal toxicity. Leukopenia, anemia, and thrombocytopenia of Grade 3 or 4 (according to the National Cancer Institute Common Toxicity Criteria) was observed in 63.0%, 30.4%, and 6.5% of the patients, respectively, and Grade 3 or 4 diarrhea occurred in 30.4% of patients. Treatment was withdrawn because of diarrhea in three patients. Because of myelosuppression and diarrhea, approximately 67% of the patients required changes to the regimen, including dose reduction, prolongation of the interval between treatments, and reducing the number of days of consecutive treatment.CONCLUSIONSThe results of the current study suggest the activity of irinotecan as salvage therapy for patients with recurrent and refractory non‐Hodgkin lymphoma. However, the optimum dosing schedule remains to be determined. Cancer 2002;94:594–600. © 2002 American Cancer Society.DOI 10.1002/cncr.10266
Tumor vaccine for ovarian carcinoma targeting sperm protein 17
Authors: Chiriva‐Internati Maurizio , Wang Zhiqing , Salati Emanuela , Timmins Patrick , Lim Seah H. 
Published: August 2002

AbstractBACKGROUNDThe authors previously identified sperm protein 17 (Sp17) as being expressed in patients with multiple myeloma. The restricted expression of Sp17 in normal tissue makes it an ideal target for tumor vaccine. In the current study, the authors extended their research to include ovarian carcinoma.METHODSA pair of sequence specific primers was used in reverse transcriptase‐polymerase chain reaction to determine the gene expression of Sp17. A recombinant Sp17 protein was used with monocyte‐derived dendritic cells and autologous peripheral blood mononuclear cells to generate Sp17 specific cytotoxic T‐lymphocytes (CTLs). The successful generation of Sp17 specific CTLs was confirmed using standard 51chromium‐release assays.RESULTSSp17 was found to be expressed in the primary tumor cells from 70% of the patients with ovarian carcinoma. Human leukocyte antigen (HLA) class I‐ restricted Sp17 specific CTLs were generated successfully from the peripheral blood of three patients with ovarian carcinoma at the time of disease presentation. These CTLs were able to lyse autologous Epstein‐Barr virus‐transformed lymphoblastoid cells in a Sp17‐dependent manner. Target lysis was HLA class I‐dependent and could be blocked by antibodies against monomorphic HLA class I but not HLA class II molecules. The CTLs also lysed Sp17‐positive autologous tumor cells, suggesting that Sp17 is processed and presented in association with the HLA class I molecules in Sp17‐ positive tumor cells in a concentration and configuration that could be recognized by recombinant protein‐primed CTLs. Tumor cell killing by the CTLs appeared to be mediated through the perforin pathway. Flow cytometric analysis of the CTLs indicated that they predominantly were CD8 in phenotype and produced interferon‐γ and scant amounts of interleukin‐4.CONCLUSIONSThe results of the current study suggest the potential of Sp17 as a target for immunotherapy in patients with ovarian carcinoma. Cancer 2002;94:2447–53. © 2002 American Cancer Society.DOI 10.1002/cncr.10506